Table Info

Table 1.

Summary of studies demonstrating crosstalks between the PTEN and PAFR as well as PAFR and EGFR pathways

Cancer model	Cell line(s)	Treatment(s)	Key findings	Reference
Breast cancer	MCF-7, MDA-MB-231	PAFR antagonist	PAFR antagonist-mediated decreased invasive behavior and G0/G1 cell cycle arrest was mediated via increased PTEN expression	[29]
Melanoma	B16F10	Ad-PTEN	Ad-PTEN blocked PAF-induced pulmonary melanoma metastasis	[31]
Ovarian cancer	OVCA 429, OVCA 432	PAFR antagonist	PAFR antagonist blocked PAF-induced activation of EGFR and downstream signaling cascades resulting in decreased cell proliferation	[34]
Ovarian cancer	SKOV3	-	PAF-PAFR signaling induced increased EGFR activation	[35]
Ovarian cancer	CAOV3, SKOV3	PAFR antagonist and EGFR inhibitor	Increased inhibition of cell proliferation and invasion and decreased tumor growth	[36]
Ovarian cancer	CAOV3, SKOV3	PAFR antagonist and EGFR inhibitor	Inhibition of the PAFR and EGFR blocked EGF-induced PAF production	[37]
Epidermal cells	KB	EGFR inhibitor	Inhibition of increased production of PAFR agonists and systemic immunosuppression	[38]
Ovarian cancer	CASKI, C33A	PAFR antagonist and EGFR inhibitor	Decreased cell viability and proliferation	[39]

PTEN: phosphatase and tensin homolog; PAFR: platelet-activating factor-receptor; EGFR: epidermal growth factor receptor; Ad-PTEN: adenovirus harboring cDNA construct of PTEN; -: no data

Declarations

Author contributions

AT: Conceptualization, Writing—original draft, Writing—review & editing. ZS: Writing—review & editing. RPS: Conceptualization, Writing—review & editing, Funding acquisition. All authors read and approved the submitted version.

Conflicts of interest

Ravi P. Sahu who is the Editorial Board Member of Exploration of Drug Science had no involvement in the decision-making or the review process of this manuscript. The other authors declare no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

The datasets analyzed in Figure 2 can be found in the TCGA GEPIA2 http://gepia.cancer-pku.cn/.

Funding

The financial support from the NIH R21 grant [ES033806] (RPS) is greatly appreciated. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Mester J, Eng C. When overgrowth bumps into cancer: the PTEN-opathies. Am J Med Genet C Semin Med Genet. 2013;163C:114–21. [DOI] [PubMed]

Pérez-Ramírez C, Canãdas-Garre M, Molina MÁ, Faus-Dáder MJ, Calleja-Hernández MÁ. PTEN and PI3K/AKT in Non-Small-Cell Lung Cancer. Pharmacogenomics. 2015;16:1843–62. [DOI] [PubMed]

Vazquez F, Matsuoka S, Sellers WR, Yanagida T, Ueda M, Devreotes PN. Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane. Proc Natl Acad Sci U S A. 2006;103:3633–8. [DOI] [PubMed] [PMC]

Wang Q, Wang J, Xiang H, Ding P, Wu T, Ji G. The biochemical and clinical implications of phosphatase and tensin homolog deleted on chromosome ten in different cancers. Am J Cancer Res. 2021;11:5833–55. [PubMed] [PMC]

Hopkins BD, Fine B, Steinbach N, Dendy M, Rapp Z, Shaw J, et al. A secreted PTEN phosphatase that enters cells to alter signaling and survival. Science. 2013;341:399–402. [DOI] [PubMed] [PMC]

Zheng C, Tang F, Min L, Hornicek F, Duan Z, Tu C. PTEN in osteosarcoma: Recent advances and the therapeutic potential. Biochim Biophys Acta Rev Cancer. 2020;1874:188405. [DOI] [PubMed]

Sirhan Z, Alojair R, Thyagarajan A, Sahu RP. Therapeutic Implications of PTEN in Non-Small Cell Lung Cancer. Pharmaceutics. 2023;15:2090. [DOI] [PubMed] [PMC]

da Silva-Jr IA, Chammas R, Lepique AP, Jancar S. Platelet-activating factor (PAF) receptor as a promising target for cancer cell repopulation after radiotherapy. Oncogenesis. 2017;6:e296. [DOI] [PubMed] [PMC]

Sahu RP, Ocana JA, Harrison KA, Ferracini M, Touloukian CE, Al-Hassani M, et al. Chemotherapeutic agents subvert tumor immunity by generating agonists of platelet-activating factor. Cancer Res. 2014;74:7069–78. [DOI] [PubMed] [PMC]

10.

Sahu RP, Konger RL, Travers JB. Platelet-Activating Factor-Receptor and Tumor Immunity. JSM Cell Dev Biol. 2014;2:1008. [PubMed] [PMC]

11.

Travers JB, Rohan JG, Sahu RP. New Insights Into the Pathologic Roles of the Platelet-Activating Factor System. Front Endocrinol (Lausanne). 2021;12:624132. [DOI] [PubMed] [PMC]

12.

Chen J, Lan T, Zhang W, Dong L, Kang N, Zhang S, et al. Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer. Cancer Res. 2015;75:4198–210. [DOI] [PubMed]

13.

Chen J, Lan T, Zhang W, Dong L, Kang N, Zhang S, et al. Platelet-activating factor receptor-mediated PI3K/AKT activation contributes to the malignant development of esophageal squamous cell carcinoma. Oncogene. 2015;34:5114–27. [DOI] [PubMed]

14.

Sahu RP, Harrison KA, Weyerbacher J, Murphy RC, Konger RL, Garrett JE, et al. Radiation therapy generates platelet-activating factor agonists. Oncotarget. 2016;7:20788–800. [DOI] [PubMed] [PMC]

15.

Gajiwala KS, Feng J, Ferre R, Ryan K, Brodsky O, Weinrich S, et al. Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition. Structure. 2013;21:209–19. [DOI] [PubMed]

16.

Colabufo NA, Contino M, Niso M, Berardi F, Leopoldo M, Perrone R. EGFR tyrosine kinase inhibitors and multidrug resistance: perspectives. Front Biosci (Landmark Ed). 2011;16:1811–23. [DOI] [PubMed]

17.

Uribe ML, Marrocco I, Yarden Y. EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers (Basel). 2021;13:2748. [DOI] [PubMed] [PMC]

18.

Zubair T, Bandyopadhyay D. Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities. Int J Mol Sci. 2023;24:2651. [DOI] [PubMed] [PMC]

19.

Zhao M, Zhang J, Gao J, Wang J, Ma Z. Osimertinib Efficacy and Safety in Treating Epidermal Growth Factor Receptor Mutation-Positive Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis. Clin Pharmacol Drug Dev. 2024;[Epub ahead of print]. [DOI] [PubMed]

20.

Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 2018;17:53. [DOI] [PubMed] [PMC]

21.

Lee J, Kim HS, Lee B, Kim HK, Sun J, Ahn JS, et al. Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer. Cancer. 2020;126:2704–12. [DOI] [PubMed]

22.

Kita Y, Shindou H, Shimizu T. Cytosolic phospholipase A₂ and lysophospholipid acyltransferases. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864:838–45. [DOI] [PubMed]

23.

Marathe GK, Prescott SM, Zimmerman GA, McIntyre TM. Oxidized LDL contains inflammatory PAF-like phospholipids. Trends Cardiovasc Med. 2001;11:139–42. [DOI] [PubMed]

24.

Sahu RP, Petrache I, Demark MJV, Rashid BM, Ocana JA, Tang Y, et al. Cigarette smoke exposure inhibits contact hypersensitivity via the generation of platelet-activating factor agonists. J Immunol. 2013;190:2447–54. [DOI] [PubMed] [PMC]

25.

Silva Junior IAd, Stone SC, Rossetti RM, Jancar S, Lepique AP. Modulation of Tumor-Associated Macrophages (TAM) Phenotype by Platelet-Activating Factor (PAF) Receptor. J Immunol Res. 2017;2017:5482768. [DOI] [PubMed] [PMC]

26.

Thyagarajan A, Alshehri MSA, Miller KLR, Sherwin CM, Travers JB, Sahu RP. Myeloid-Derived Suppressor Cells and Pancreatic Cancer: Implications in Novel Therapeutic Approaches. Cancers (Basel). 2019;11:1627. [DOI] [PubMed] [PMC]

27.

Thyagarajan A, Kadam SM, Liu L, Kelly LE, Rapp CM, Chen Y, et al. Gemcitabine Induces Microvesicle Particle Release in a Platelet-Activating Factor-Receptor-Dependent Manner via Modulation of the MAPK Pathway in Pancreatic Cancer Cells. Int J Mol Sci. 2018;20:32. [DOI] [PubMed] [PMC]

28.

Chauhan SJ, Thyagarajan A, Chen Y, Travers JB, Sahu RP. Platelet-Activating Factor-Receptor Signaling Mediates Targeted Therapies-Induced Microvesicle Particles Release in Lung Cancer Cells. Int J Mol Sci. 2020;21:8517. [DOI] [PubMed] [PMC]

29.

Cellai C, Laurenzana A, Vannucchi AM, Caporale R, Paglierani M, Lollo SD, et al. Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086. Br J Cancer. 2006;94:1637–42. [DOI] [PubMed] [PMC]

30.

Bussolati B, Biancone L, Cassoni P, Russo S, Rola-Pleszczynski M, Montrucchio G, et al. PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am J Pathol. 2000;157:1713–25. [DOI] [PubMed] [PMC]

31.

Kim H, Kim K, Seo KH, Lee H, Im S. PTEN/MAPK pathways play a key role in platelet-activating factor-induced experimental pulmonary tumor metastasis. FEBS Lett. 2012;586:4296–302. [DOI] [PubMed]

32.

Alshehri E, Al-Dogmi AM, Al-Hazani TMI, Alwaili MA, Safhi FA, Alneghery LM, et al. Patterns of mutations in nine cancer-related genes and PAF development among smoking male patients diagnosed with bladder cancer. Tumour Biol. 2023;45:1–14. [DOI] [PubMed]

33.

Kang N, Yoon H, Kim H, Kim K, Han M, Lee Y, et al. Protein kinase CK2/PTEN pathway plays a key role in platelet-activating factor-mediated murine anaphylactic shock. J Immunol. 2011;186:6625–32. [DOI] [PubMed]

34.

Aponte M, Jiang W, Lakkis M, Li M, Edwards D, Albitar L, et al. Activation of platelet-activating factor receptor and pleiotropic effects on tyrosine phospho-EGFR/Src/FAK/paxillin in ovarian cancer. Cancer Res. 2008;68:5839–48. [DOI] [PubMed] [PMC]

35.

Yu Y, Zhang M, Zhang X, Cai Q, Zhu Z, Jiang W, et al. Transactivation of epidermal growth factor receptor through platelet-activating factor/receptor in ovarian cancer cells. J Exp Clin Cancer Res. 2014;33:85. [DOI] [PubMed] [PMC]

36.

Yu Y, Zhang M, Zhang X, Cai Q, Hong S, Jiang W, et al. Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells. J Hematol Oncol. 2014;7:39. [DOI] [PubMed] [PMC]

37.

Yu Y, Zhang X, Hong S, Zhang M, Cai Q, Jiang W, et al. Epidermal growth factor induces platelet-activating factor production through receptors transactivation and cytosolic phospholipase A2 in ovarian cancer cells. J Ovarian Res. 2014;7:39. [DOI] [PubMed] [PMC]

38.

Yao Y, Wolverton JE, Zhang Q, Marathe GK, Al-Hassani M, Konger RL, et al. Ultraviolet B radiation generated platelet-activating factor receptor agonist formation involves EGF-R-mediated reactive oxygen species. J Immunol. 2009;182:2842–8. [DOI] [PubMed] [PMC]

39.

Souza JL, Martins-Cardoso K, Guimarães IS, Melo ACd, Lopes AH, Monteiro RQ, et al. Interplay Between EGFR and the Platelet-Activating Factor/PAF Receptor Signaling Axis Mediates Aggressive Behavior of Cervical Cancer. Front Oncol. 2020;10:557280. [DOI] [PubMed] [PMC]

40.

Morimoto R, Shindou H, Oda Y, Shimizu T. Phosphorylation of lysophosphatidylcholine acyltransferase 2 at Ser34 enhances platelet-activating factor production in endotoxin-stimulated macrophages. J Biol Chem. 2010;285:29857–62. [DOI] [PubMed] [PMC]

41.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98–102. [DOI] [PubMed] [PMC]